Context Therapeutics Inc.CNTXEarnings & Financial Report
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for hormone-driven cancers. Its core pipeline includes candidates for breast, ovarian and other gynecologic malignancies, primarily serving oncology patient populations across North America and Europe.
CNTX Q3 FY2024 Key Financial Metrics
Revenue
$1.2M
Gross Profit
N/A
Operating Profit
$-18.7M
Net Profit
$-17.5M
Gross Margin
N/A
Operating Margin
-1503.7%
Net Margin
-1403.9%
YoY Growth
328.2%
EPS
$-0.22
Context Therapeutics Inc. Q3 FY2024 Financial Summary
Context Therapeutics Inc. reported revenue of $1.2M (up 328.2% YoY) for Q3 FY2024, with a net profit of $-17.5M (down 197.2% YoY) (-1403.9% margin).
Key Financial Metrics
| Total Revenue | $1.2M |
|---|---|
| Net Profit | $-17.5M |
| Gross Margin | N/A |
| Operating Margin | -1503.7% |
| Report Period | Q3 FY2024 |
Context Therapeutics Inc. Annual Revenue by Year
Context Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $1.2M).
Context Therapeutics Inc. Quarterly Revenue & Net Profit History
Context Therapeutics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $1.2M | +328.2% | $-17.5M | -1403.9% |
| Q2 FY2024 | $840.1K | +186.5% | $-2.3M | -268.3% |
| Q4 FY2023 | $224.7K | -31.5% | $-6.8M | -3012.6% |
| Q3 FY2023 | $290.4K | +51.1% | $-5.9M | -2022.7% |
| Q2 FY2023 | $293.3K | +1277.1% | $-5.0M | -1708.8% |
| Q1 FY2023 | $355.5K | +5963.1% | $-6.3M | -1774.3% |
| Q4 FY2022 | $327.9K | — | $-3.6M | -1084.8% |
| Q3 FY2022 | $192.2K | +15345.4% | $-3.9M | -2004.9% |
Income Statement
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $192245 | $327863 | $355542 | $293274 | $290440 | $224719 | $840150 | $1.2M |
| YoY Growth | 15345.4% | N/A | 5963.1% | 1277.1% | 51.1% | -31.5% | 186.5% | 328.2% |
Balance Sheet
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $42.1M | $38.0M | $32.0M | $27.8M | $23.0M | $16.1M | $102.7M | $86.3M |
| Liabilities | $4.0M | $3.2M | $3.2M | $3.8M | $4.6M | $4.2M | $1.6M | $2.5M |
| Equity | $38.1M | $34.8M | $28.7M | $24.0M | $18.4M | $11.9M | $101.1M | $83.9M |
Cash Flow
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.0M | $-3.9M | $-5.7M | $-4.6M | $-3.5M | $-7.2M | $-3.4M | $-1.9M |